Grace Therapeutics (GRCE) Research & Development (2019 - 2026)
Grace Therapeutics (GRCE) posted Research & Development of $420000.0 for Q1 2026, down 9.09% sequentially from $462000.0 in Q4 2025, and down 74.3% YoY from $1.6 million in Q1 2025.
Grace Therapeutics (GRCE) Research & Development (2019 - 2026) Analysis & Trends
Grace Therapeutics has reported Research & Development for 8 years, with the latest figure at $420000.0 in Q1 2026.
- Quarterly Research & Development fell 74.3% year-over-year to $420000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.4 million (down 74.72% YoY) and the FY2026 annual result came in at $2.4 million, down 74.71% from the prior year.
- Research & Development slipped to $420000.0 in Q1 2026 per GRCE's latest filing, from $462000.0 in the prior quarter.
- Over five years, Research & Development peaked at $3.0 million in Q3 2024 and troughed at $136000.0 in Q3 2022.
- A 5-year average of $1.5 million and a median of $1.6 million in 2025 frame the typical range for Research & Development.
- The sharpest annual moves came in 2024 and 2025: Research & Development surged 546.96% in 2024, then plunged 80.91% in 2025.
- Over 5 years, Research & Development stood at $2.4 million in 2022, then sank by 41.1% to $1.4 million in 2023, then soared by 52.04% to $2.2 million in 2024, then plunged by 78.94% to $462000.0 in 2025, then dropped by 9.09% to $420000.0 in 2026.
- According to Business Quant data, Research & Development over the past three periods registered $420000.0, $462000.0, and $568000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 413.13 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 210.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 97.90 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -588.31 Mn |
| 10 | Grace Therapeutics | 37.04 Mn | 37.04 Mn | - | 697,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 697,000.00 |
| Mar 31, 2026 | 420,000.00 |
| Dec 31, 2025 | 462,000.00 |
| Sep 30, 2025 | 568,000.00 |
| Jun 30, 2025 | 955,000.00 |
| Mar 31, 2025 | 1.63 Mn |
| Dec 31, 2024 | 2.19 Mn |
| Sep 30, 2024 | 2.98 Mn |
| Jun 30, 2024 | 2.71 Mn |
| Mar 31, 2024 | 1.69 Mn |
| Dec 31, 2023 | 1.44 Mn |
| Sep 30, 2023 | 460,000.00 |
| Jun 30, 2023 | 1.10 Mn |
| Mar 31, 2023 | 1.64 Mn |
| Dec 31, 2022 | 2.45 Mn |
| Sep 30, 2022 | 136,000.00 |
| Jun 30, 2022 | 2.59 Mn |
| Mar 31, 2022 | 2.33 Mn |
| Dec 31, 2021 | 2.18 Mn |
| Sep 30, 2021 | 585,000.00 |